CR Double-Crane's subsidiary Bosentan dispersible tablets have obtained a drug registration certificate
I'm PortAI, I can summarize articles.
CR Double-Crane's wholly-owned subsidiary CR Double-Crane Limin Pharmaceutical (Jinan) Co., Ltd. recently received the Drug Registration Certificate for Bosentan Dispersible Tablets issued by the National Medical Products Administration. This medication is suitable for pediatric patients aged 3 years and older with idiopathic or congenital pulmonary arterial hypertension (PAH), as well as adult PAH patients classified as WHO functional class II to IV
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments